1. Damsky W, King BA (2017) JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol 76(4):736–744
2. RINVOQ: Highlights of Prescribing Information. 2022.
3. A study of baricitinib (LY3009104) in participants with severe or very severe alopecia areata (BRAVE-AA1). ClinicalTrials.gov identifier: NCT03570749. 2022.
4. A study of baricitinib (LY3009104) in adults with severe or very severe alopecia areata (BRAVE-AA2). ClinicalTrials.gov identifier: NCT03899259. 2022. Available from: https://clinicaltrials.gov/ct2/show/NCT03899259.
5. Unpublished internal company data - Eli Lilly and Company. 2022.